Is Vertex Pharmaceuticals Incorporated (VRTX) a Buy, Sell, or Hold?
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$476.31 USD
-$3.94 (-0.82%)
- Volume
- 1.09M
- Average Volume
- 1.49M
- Market Capitalization
- $120.89B
- P/E Ratio
- 28.00
- Dividend Yield
- 0.00%
- Price Target
- $572.00
- Year High
- $533.67
- Year Low
- $362.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.02
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Reshma Kewalramani |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VRTX |
| CUSIP | 92532F100 |
| CIK | 0000875320 |
| Web | https://www.vrtx.com |
| Phone | 617 341 6100 |
| Currency | USD |
| Employees | 6400 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.02 |
| Quick Ratio | 2.57 |
| Cash Ratio | 1.42 |
Sales & Book Value
| Annual Sales | $12.07B |
| Price / Sales | 9.86 |
| Cash Flow | 14.60 |
| Price / Cash Flow | 32.58 |
| Price / Book | 6.25 |
Price Target and Rating
| Average Stock Price Forecast | $572.00 |
| High Stock Price Forecast | $616.00 |
| Low Stock Price Forecast | $350.00 |
| Forecast Upside/Downside | -16.73% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 56 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $15.32 |
| Trailing P/E Ratio | 28.00 |
| PEG Ratio | 0.05 |
| P/E Growth | 0.05 |
| Net Income | $3.95B |
| Net Margin | 35.40% |
| Pretax Margin | 42.15% |
| Return on Equity | 23.93% |
| Return on Assets | 16.38% |
Financials Score
| AltmanZ Score | 12.50 |
| Piotroski Score | 5.00 |
| Working Capital | 7.85B |
| Total Assets | 26.48B |
| Ebit | 5.18B |
| Market Cap | 121.89B |
| Total Liabilities | 7.12B |
Poll Results
About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosc ... lerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
2026-07-14 08:00:00
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
2026-07-13 19:01:06
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
2026-07-13 14:27:07
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
2026-07-11 17:03:07
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Is This Biotech Stock a Buy Near Its 52-Week High?
2026-07-10 17:00:00
Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still performing well.
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
2026-07-10 04:05:00
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.
Why Crinetics Stock Soared 99% This Week
2026-07-09 13:29:39
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
2026-07-09 11:35:25
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Frequently Asked Questions
-
What is the current Vertex Pharmaceuticals Incorporated (VRTX) stock price?
-
Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX) stock price is $476.31 in the last trading session. During the trading session, VRTX stock reached the peak price of $533.67 while $362.5 was the lowest point it dropped to. The percentage change in VRTX stock occurred in the recent session was --0.82% while the dollar amount for the price change in VRTX stock was -$-3.94.
-
VRTX's industry and sector of operation?
-
The NASDAQ listed VRTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VRTX?
-
Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer
Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer
Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer
Reshma Kewalramani FASN | Chief Executive Officer, President & Director
Jeffrey Marc Leiden | Executive Chairman -
How many employees does VRTX have?
-
Number of VRTX employees currently stands at 6400. VRTX operates from 50 Northern Avenue, Boston, MA 02210, US.
-
Link for VRTX official website?
-
Official Website of VRTX is: https://www.vrtx.com
-
How do I contact VRTX?
-
VRTX could be contacted at phone #617 341 6100 and can also be accessed through its website. VRTX operates from 50 Northern Avenue, Boston, MA 02210, US.
-
How many shares of VRTX are traded daily?
-
The average number of VRTX shares traded daily for last 3 months was 1.49M.
-
What is the market cap of VRTX currently?
-
The market value of VRTX currently stands at $120.89B with its latest stock price at $476.31